{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:55:03Z","timestamp":1793692503239,"version":"4.5.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.biomaterials.2024.122904","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T03:08:52Z","timestamp":1729566532000},"page":"122904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Amplifying glioblastoma immunotherapy: T cell shielding through Nitric oxide\/reactive oxygen species scavenging nanoparticles Potentiates anti-PD-1"],"prefix":"10.1016","volume":"315","author":[{"given":"Jihye","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeoul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyori","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurusamy","family":"Saravanakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon A","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1597","authenticated-orcid":false,"given":"Stephen","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4064-0999","authenticated-orcid":false,"given":"Won Jong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biomaterials.2024.122904_bib1","article-title":"Immunotherapy for glioblastoma: current progress and challenges","volume":"12","author":"Yu","year":"2021","journal-title":"Front. Immunol."},{"issue":"61","key":"10.1016\/j.biomaterials.2024.122904_bib2","article-title":"Overall survival prediction in glioblastoma with radiomic features using machine learning","volume":"14","author":"Baid","year":"2020","journal-title":"Front Comput Neurosc"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"issue":"45","key":"10.1016\/j.biomaterials.2024.122904_bib4","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1038\/onc.2016.85","article-title":"A comprehensive profile of recurrent glioblastoma","volume":"35","author":"Campos","year":"2016","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib5","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib7","article-title":"A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet","volume":"6","author":"D'Errico","year":"2017","journal-title":"Clin. Transl. Med."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122904_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/11594010-000000000-00000","article-title":"Ipilimumab: first global approval","volume":"71","author":"Cameron","year":"2011","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122904_bib9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122904_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2022.105932","article-title":"Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and\/or a primary subsite excluded from CheckMate141, a retrospective study","volume":"130","author":"Ueda","year":"2022","journal-title":"Oral Oncol."},{"issue":"6430","key":"10.1016\/j.biomaterials.2024.122904_bib12","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy (vol 363, eaar3593, 2019)","volume":"363","author":"Cristescu","year":"2019","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 Phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s11060-016-2190-1","article-title":"Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors","volume":"129","author":"Blumenthal","year":"2016","journal-title":"J. Neuro Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122904_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163447","article-title":"Immune checkpoint blockade in glioblastoma from tumor heterogeneity to personalized treatment","volume":"133","author":"Arrieta","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122904_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib17","article-title":"Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators (vol 11, 79, 2023)","volume":"11","author":"Segura-Collar","year":"2023","journal-title":"Acta Neuropathol Com"},{"issue":"5","key":"10.1016\/j.biomaterials.2024.122904_bib18","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/labinvest.2017.19","article-title":"Immune microenvironment of gliomas","volume":"97","author":"Gieryng","year":"2017","journal-title":"Lab. Invest."},{"key":"10.1016\/j.biomaterials.2024.122904_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672508","article-title":"Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma","volume":"11","author":"Frederico","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells10010018","article-title":"Myeloid cells in glioblastoma microenvironment","volume":"10","author":"De Leo","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J Exp Clin Canc Res"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib22","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-020-03481-0","article-title":"Combination immunotherapy strategies for glioblastoma","volume":"151","author":"Chan","year":"2021","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib23","first-page":"212","article-title":"Combining radiation therapy with immune checkpoint blockade for central nervous system malignancies","volume":"6","author":"D'Souza","year":"2016","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11060-020-03481-0","article-title":"Combination immunotherapy strategies for glioblastoma","volume":"151","author":"Chan","year":"2021","journal-title":"J. Neuro Oncol."},{"issue":"25","key":"10.1016\/j.biomaterials.2024.122904_bib26","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.biomaterials.2024.122904_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000477162","article-title":"PD-1 checkpoint inhibitor associated autoimmune encephalitis","volume":"10","author":"Schneider","year":"2017","journal-title":"Case Rep. Oncol."},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41423-020-00613-4","article-title":"Tumor-associated myeloid cells: diversity and therapeutic targeting","volume":"18","author":"Mantovani","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01473-x","article-title":"Tumor-associated myeloid cells in cancer immunotherapy","volume":"16","author":"Cheng","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.biomaterials.2024.122904_bib30","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res."},{"issue":"47","key":"10.1016\/j.biomaterials.2024.122904_bib31","doi-asserted-by":"crossref","first-page":"23714","DOI":"10.1073\/pnas.1906346116","article-title":"Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma","volume":"116","author":"Zhang","year":"2019","journal-title":"P Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122904_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc8929","article-title":"Polyamines drive myeloid cell survival by buffering intracellular pH to promote immunosuppression in glioblastoma","volume":"7","author":"Miska","year":"2021","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib33","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nn.4185","article-title":"The role of microglia and macrophages in glioma maintenance and progression","volume":"19","author":"Hambardzumyan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"8","key":"10.1016\/j.biomaterials.2024.122904_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081785","article-title":"Role of tumor-associated myeloid cells in breast cancer","volume":"9","author":"Cha","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biomaterials.2024.122904_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114585","article-title":"Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy","volume":"191","author":"Zhao","year":"2022","journal-title":"Adv Drug Deliver Rev"},{"issue":"11","key":"10.1016\/j.biomaterials.2024.122904_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111958","article-title":"Pro-tumoral inflammatory myeloid cells as emerging therapeutic targets","volume":"17","author":"Szebeni","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib37","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/cr.2013.75","article-title":"ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages","volume":"23","author":"Zhang","year":"2013","journal-title":"Cell Res."},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122904_bib38","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1007\/s00018-020-03536-5","article-title":"The multifaceted role of reactive oxygen species in tumorigenesis","volume":"77","author":"Kirtonia","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"issue":"9","key":"10.1016\/j.biomaterials.2024.122904_bib39","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.4049\/jimmunol.0900092","article-title":"Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells","volume":"182","author":"Corzo","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.707198","article-title":"Myeloid-derived suppressor cells: implications in the resistance of malignant tumors to T cell-based immunotherapy","volume":"9","author":"Shi","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","article-title":"Altered recognition of antigen is a mechanism of CD8 T cell tolerance in cancer","volume":"13","author":"Nagaraj","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.biomaterials.2024.122904_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive oxygen species as regulators of MDSC-mediated immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib43","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1002\/eji.201040868","article-title":"Modulation of human T-cell functions by reactive nitrogen species","volume":"41","author":"Kasic","year":"2011","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122904_bib44","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.4049\/jimmunol.162.6.3356","article-title":"Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death","volume":"162","author":"Brito","year":"1999","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122904_bib45","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.4049\/jimmunol.0902661","article-title":"Mechanism of T Cell tolerance induced by myeloid-derived suppressor cells","volume":"184","author":"Nagaraj","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib46","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4197815","article-title":"Reactive oxygen species in cancer biology and anticancer therapy","volume":"2016","author":"Bazhin","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122904_bib47","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.biomaterials.2024.122904_bib48","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","article-title":"Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells","volume":"208","author":"Molon","year":"2011","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.biomaterials.2024.122904_bib49","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression, Brit","volume":"120","author":"Groth","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.biomaterials.2024.122904_bib50","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1580967","article-title":"Reactive oxygen species regulate T cell immune response in the tumor microenvironment","volume":"2016","author":"Chen","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"22","key":"10.1016\/j.biomaterials.2024.122904_bib51","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.1074\/jbc.M111451200","article-title":"Reactive oxygen species differentially affect T cell receptor-signaling pathways","volume":"277","author":"Cemerski","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biomaterials.2024.122904_bib52","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0961-y","article-title":"Reactive oxygen species: a volatile driver of field cancerization and metastasis","volume":"18","author":"Liao","year":"2019","journal-title":"Mol. Cancer"},{"issue":"7","key":"10.1016\/j.biomaterials.2024.122904_bib53","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1039\/D2BM01994A","article-title":"Nitric oxide scavengers based on o-phenylenediamine for the treatment of rheumatoid arthritis","volume":"11","author":"Lee","year":"2023","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.biomaterials.2024.122904_bib54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2015.09.057","article-title":"Self-assembled 20-nm Cu-micelles enhance accumulation in rat glioblastoma","volume":"220","author":"Seo","year":"2015","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biomaterials.2024.122904_bib55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.freeradbiomed.2021.12.002","article-title":"Breaking barriers: neurodegenerative repercussions of radiotherapy induced damage on the blood-brain and blood-tumor barrier","volume":"178","author":"Allen","year":"2022","journal-title":"Free Radical Bio Med"},{"key":"10.1016\/j.biomaterials.2024.122904_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.622615","article-title":"The normal and brain tumor vasculature: morphological and functional characteristics and therapeutic targeting","volume":"12","author":"Guyon","year":"2021","journal-title":"Front. Physiol."},{"issue":"20","key":"10.1016\/j.biomaterials.2024.122904_bib57","doi-asserted-by":"crossref","first-page":"12716","DOI":"10.1021\/acsnano.3c08993","article-title":"Receptor ligand-free mesoporous silica nanoparticles: a streamlined strategy for targeted drug delivery across the blood-brain barrier","volume":"18","author":"Chen","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.biomaterials.2024.122904_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.addr.2013.09.006","article-title":"Multifunctional nanoparticles for brain tumor imaging and therapy","volume":"66","author":"Cheng","year":"2014","journal-title":"Adv Drug Deliver Rev"},{"issue":"6","key":"10.1016\/j.biomaterials.2024.122904_bib59","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4155\/tde.13.38","article-title":"Therapeutic nanomedicine for brain cancer","volume":"4","author":"Tzeng","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.biomaterials.2024.122904_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.00542","article-title":"An injectable hydrogel platform for sustained delivery of anti-inflammatory nanocarriers and induction of regulatory T cells in atherosclerosis","volume":"8","author":"Yi","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.biomaterials.2024.122904_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120675","article-title":"In Situ implantable, post-trauma microenvironment-responsive, ROS Depletion Hydrogels for the treatment of Traumatic brain injury","volume":"270","author":"Qian","year":"2021","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.biomaterials.2024.122904_bib62","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-05738-8","article-title":"Fatostatin induces ferroptosis through inhibition of the AKT\/mTORC1\/GPX4 signaling pathway in glioblastoma","volume":"14","author":"Cai","year":"2023","journal-title":"Cell Death Dis."}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224004381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961224004381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T14:13:36Z","timestamp":1735049616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961224004381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":62,"alternative-id":["S0142961224004381"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122904","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amplifying glioblastoma immunotherapy: T cell shielding through Nitric oxide\/reactive oxygen species scavenging nanoparticles Potentiates anti-PD-1","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122904"}}